2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3540 A real-world analysis of outcomes across treatment eras in mantle cell lymphoma

Sandra Jones, MD, Angelo Marra2, Subir Goyal, Ph.D3, Jonathon B. Cohen, MD, MS4
1 Emory University, Atlanta, Georgia, United States
2 Emory University, Atlanta, Georgia, United States
3 Emory University, Atlanta, Georgia, United States
4 Emory University, Atlanta, Georgia, United States

Background

Although mantle cell lymphoma (MCL) has historically been considered an aggressive form of non-Hodgkin lymphoma with inferior survival outcomes, many recent changes in treatment approach have aimed to improve survival for more recently diagnosed patients. Treatment paradigms have recently shifted from intensive chemoimmunotherapy and autologous stem cell transplant for eligible patients to novel, targeted treatment strategies including but not limited to Bruton’s tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cell (CAR-T). We evaluated trends in survival to assess relative outcomes by period of diagnosis for patients with MCL and described any trends in overall survival (OS) in the US.

Methods

We queried the National Cancer Database (NCDB) for adult patients with MCL diagnosed between 2004 and 2023. Patients were excluded if follow-up data were incomplete. The primary endpoint was OS. Treatment eras were defined as Era 1 (2004-2008), Era 2 (2009-2013), Era 3 (2014-2018), and Era 4 (2019-2023). Baseline characteristics across treatment eras were compared using the Chi-square test for categorical variables and ANOVA for continuous variables, where appropriate.

OS was measured from the date of diagnosis and estimated using the Kaplan-Meier (KM) method; survival curves were compared using the log-rank test. Univariable and multivariable Cox proportional hazards models were constructed to evaluate factors independently associated with overall survival. P values of ≤0.05 were considered significant. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results

This retrospective cohort included 34,535 patients with MCL, of whom 57.5% were> 65 years, 71.4% were male, 91.3% were white, and 10.1% identified as Spanish or Hispanic. Most patients had a Charlson-Deyo Score of 0 (76.9%) and were stage III or IV at diagnosis (85.2).

When evaluated by treatment era, fewer patients received chemotherapy in Era 4 (70.2%) compared to Era 1 (78.7%), while more patients received immunotherapy in Era 4 (65.8%) compared to Era 3 (64.2%), Era 2 (25.8%), and Era 1 (8.4%). The utilization of bone marrow or stem cell transplantation decreased over time, from 16.0% at its peak in Era 2 to 9.3% in Era 4.

Median OS was 5.6 years, 7.0 years, 7.4 years, and unable to be calculated for Eras 1 through 4, respectively; all log-rank p<0.001. Three-year OS was 63.4%, 67.6%, 68.6%, and 69.5% for Eras 1 through 4, respectively. Five-year OS was 52.3%, 58.0%, 58.3%, and 58.3% for Eras 1 through 4, respectively.

After adjusting for age, transplantation status, biologic sex, comorbidity score, treatment location, and stage, treatment in a more recent era was independently associated with lower hazards of death when compared to Era 1. The adjusted hazard ratios (aHR) were 0.87 (95%CI, 0.83-0.90) in Era 2, 0.80 (95%CI, 0.76-0.83) in Era 3, and 0.71 (95%CI, 0.67-0.76) in Era 4. Younger age was associated with superior outcomes (aHR, 0.48; 95%CI, 0.46-0.50) compared with patients ≥65 years. Male sex was associated with increased hazard of death (aHR, 1.15; 95%CI, 1.11-1.19). Patients undergoing transplantation had a lower hazard of death than those who did not (aHR, 0.54; 95%CI, 0.51-0.57).

Conclusions

We continue to see improving survival outcomes among patients with MCL as treatment eras have advanced, moving from a median OS of 5.6 years for patients diagnosed between 2004 and 2008 to over 7 years in subsequent eras. These findings support the notion of improvement in early survival rates, but longer follow-up is needed to better describe emerging trends in more recent eras. This trend persists despite increasing age at diagnosis and less utilization of intensive approaches such as autologous stem cell transplantation. We hypothesize that this trend is likely a result of increased uptake of targeted treatment strategies and cellular therapies, which have mitigated some of the historical barriers to treating older and/or transplant-ineligible patients, especially in the relapsed/refractory setting where outcomes have historically been very poor.

Sandra Jones, MD: No relevant conflicts of interest to declare.